In December 2018, the US Food and Drug Administration (FDA) published a framework for its program to explore the use of real-world evidence to help support new indications for drugs that are already approved or to help support or satisfy postapproval study requirements. The framework reflects a larger initiative to explore and pilot the utility of a variety of evidence types and technological innovations that may enhance and accelerate drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据